Calidi Biotherapeutics appoints Dr. Corsee Sanders to board; board expands to six

Calidi Biotherapeutics, Inc.

Dr. Corsee Sanders appointed as Class III director effective June 17, 2026, term to 2029 annual meeting.
Board size increased from 5 to 6; Scott Leftwich removed from Audit Committee but remains on board.
Sanders brings 30+ years pharma experience including Genentech/Roche SVP and Juno/Celgene EVP roles.
Initial equity award for Sanders deferred pending board assessment of available shares under equity plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.